Journal of Clinical Oncology, Vol 10, 364-370, Copyright © 1992 by American Society of Clinical Oncology

ARTICLES

2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia

VM Santana, J Mirro Jr, C Kearns, MJ Schell, W Crom and RL Blakley
Department of Hematology-Oncology, St Jude Children's Research Hospital, Memphis, TN 38101.

PURPOSE: The purine analog 2-chlorodeoxyadenosine (2-CDA) was well tolerated and showed promising anti-leukemic activity in a phase I trial conducted at St Jude Children's Research Hospital. To substantiate and extend this result, we performed a phase II trial in a representative group of children and young adults with relapsed acute leukemia. PATIENTS AND METHODS: Twenty-four patients (median age, 11 years) with acute myeloid or lymphoid leukemia in first or later relapse (acute myeloid leukemia [AML], 17; acute lymphoid leukemia [ALL], seven) were given continuous infusion 2-CDA for 5 days at 8.9 mg/m2/d. Patients with residual blast cells 10 days after treatment received a second course of 2-CDA that was identical to the first. Detailed pharmacokinetic studies were performed on plasma collected from five patients. RESULTS: Eight (47%) of the 17 patients with AML had complete hematologic remissions (four after the initial course of 2- CDA), and two (12%) had partial remissions, for a total response rate of 59%. Only one child with ALL achieved remission. Seven of the responding patients underwent allogeneic or autologous bone marrow transplantation, with six remaining free of leukemia for a median of 7 months (range, 1 to 11 months). The major form of drug-induced toxicity was hematologic, with severe neutropenia and thrombocytopenia (National Cancer Institute [NCI] grade 3 or 4) developing in 34 of the 36 courses of 2-CDA. In responding patients, the median times to recovery of neutrophil counts greater than 0.5 x 10(9)/L and platelet counts greater than 50 x 10(9)/L were 18 and 21 days, respectively. There were no deaths due to toxicity. The mean steady-state plasma concentration of 2-CDA was 34.6 nmol/L (range, 20 to 54 nmol/L). CONCLUSION: 2-CDA given by prolonged continuous infusion has clinically significant activity against AML and merits further testing in multidrug regimens for this disease.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				G. J.L. Kaspers and C. M. Zwaan Pediatric acute myeloid leukemia: towards high-quality cure of all patients Haematologica, November 1, 2007; 92(11): 1519 - 1532. [Abstract] [Full Text] [PDF]

				S. Jeha, V. Gandhi, K. W. Chan, L. McDonald, I. Ramirez, R. Madden, M. Rytting, M. Brandt, M. Keating, W. Plunkett, et al. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia Blood, February 1, 2004; 103(3): 784 - 789. [Abstract] [Full Text] [PDF]

				R. J. Wells, M. T. Adams, T. A. Alonzo, R. J. Arceci, J. Buckley, A. B. Buxton, K. Dusenbery, A. Gamis, M. Masterson, T. Vik, et al. Mitoxantrone and Cytarabine Induction, High-Dose Cytarabine, and Etoposide Intensification for Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia: Children's Cancer Group Study 2951 J. Clin. Oncol., August 1, 2003; 21(15): 2940 - 2947. [Abstract] [Full Text] [PDF]

				A. Pardanani, R. L. Phyliky, C.-Y. Li, and A. Tefferi 2-Chlorodeoxyadenosine Therapy for Disseminated Langerhans Cell Histiocytosis Mayo Clin. Proc., March 1, 2003; 78(3): 301 - 306. [Abstract] [PDF]

				K. R. Crews, V. Gandhi, D. K. Srivastava, B. I. Razzouk, X. Tong, F. G. Behm, W. Plunkett, S. C. Raimondi, C.-H. Pui, J. E. Rubnitz, et al. Interim Comparison of a Continuous Infusion Versus a Short Daily Infusion of Cytarabine Given in Combination With Cladribine for Pediatric Acute Myeloid Leukemia J. Clin. Oncol., October 15, 2002; 20(20): 4217 - 4224. [Abstract] [Full Text] [PDF]

				R. A. Krance, C. A. Hurwitz, D. R. Head, S. C. Raimondi, F. G. Behm, K. R. Crews, D. K. Srivastava, H. Mahmoud, W. M. Roberts, X. Tong, et al. Experience With 2-Chlorodeoxyadenosine in Previously Untreated Children With Newly Diagnosed Acute Myeloid Leukemia and Myelodysplastic Diseases J. Clin. Oncol., June 1, 2001; 19(11): 2804 - 2811. [Abstract] [Full Text] [PDF]

				K. Lotfi, E. Mansson, T. Spasokoukotskaja, B. Pettersson, J. Liliemark, C. Peterson, S. Eriksson, and F. Albertioni Biochemical Pharmacology and Resistance to 2-Chloro-2'-arabino-fluoro-2'-deoxyadenosine, a Novel Analogue of Cladribine in Human Leukemic Cells Clin. Cancer Res., September 1, 1999; 5(9): 2438 - 2444. [Abstract] [Full Text] [PDF]

				A. Saven and C. Burian Cladribine Activity in Adult Langerhans-Cell Histiocytosis Blood, June 15, 1999; 93(12): 4125 - 4130. [Abstract] [Full Text] [PDF]

				A. K Morris, J. M Kolesar, and J. G Kuhn Review : Purine nucleoside analogs: fludarabine, entostatin and cladribine: Part 3: cladribine Journal of Oncology Pharmacy Practice, June 1, 1997; 3(2): 94 - 109. [PDF]